公开(公告)号：EP3403099A1

公开(公告)日：2018-11-21

申请号：EP17739022.6

申请日：2017-01-13

申请人： The Wistar Institute Of Anatomy And Biology

发明人： ERTL, Hildegund C. J. ,  ZHANG, Ying

IPC分类号： G01N33/574 ,  A61K31/00 ,  A61K35/26 ,  A61K39/00 ,  A61K35/17 ,  C12N5/0783

CPC分类号： A61K31/216 ,  A61K31/192 ,  A61K31/195 ,  A61K35/17 ,  A61K35/26 ,  A61K39/0011 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55516 ,  C07K16/2818 ,  C12N5/0635 ,  C12N2510/00 ,  C12N2710/10043 ,  G01N33/574

摘要： Methods for treating cancer are disclosed which comprise administering to a subject T cells which have been pretreated ex vivo or in vitro with a fatty acid catabolism promoter to condition the T cell to use fatty acids rather than glucose for energy production. Still other methods comprise co-administering to a subject having a cancer characterized by a solid tumor (a) an immunotherapeutic composition targeting an antigen or ligand on the tumor cell; and (b) a compound or reagent that promotes the use of fatty acid catabolism by tumor antigen-specific T cells in the tumor microenvironment and/or T cells pretreated ex vivo with the fatty acid catabolism promoter to condition the T cell to use fatty acids rather than glucose for energy production for adoptive cell transfer. Both methods may also employ co-administration of a checkpoint inhibitor.